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Polyclonal antibodies were raised in rabbits against the GABA,,-rcccptor 83 subunit peptidc scqucncc. KQSMPREGHGRHMDR-NH, coupled 
to key,hoic limpet haemocyanin. These anti-/33 3?9-393 antibodies immunoprccipitatcd in a dose-dcpcndcnt manner specific bcnzodiazcpinc agonist 
binding sites from Na’ dcoxycholatc extracts of bovine ccrcbral cortex. In immunoblots, anti-/33 379-393 antibodies rccogniscd two species with 
M, 59 900 and Jf, 57 200 in all preparations tcstcd, which included crude dctcrgcnt-solubiliscd, benzodiazcpinc alhnity chromatography-purified 
receptor, anti-al 324-311 antibody, anti-Cys a2 414-424 antibody and anti-Cys a3 4Sti67 antibody immunoathnity-purified GABA,\-rcccptor 
subpopulations. Thcsc results pro+i:lc cvidencc for the ubiquity and promiscuity OT the GABA,,-rcccptor p3 subunit. 
GABA,,; Receptor; Bcnzodiazcpinc; Antibody; ImmunoalIinity; Purification 
1 s INTRODUCTION 
The ^/-aminobutyric acid,, (GABA,,)-receptors of 
mammalian brain are chloride ion channels whose func- 
tion can be allostericaliy regulated by benzodiazepines, 
barbiturates and neurosteroids [I]. Molecular cloning 
has revealed an extensive family of GABA,-receptor 
subunit genes whose products, on the basis of their 
deduced amino acid seqc-?ce similarities, can be divi- 
ded into five distinct subunit types designated a, p, y, 
8 and p. Within each subunit class, isoforms exist i.e. 
al-~6, PI-j34 and ~1-~3 which share at least 75% 
amino acid sequence identity [2]. Two examples of alter- 
native spiicing of GABA,-receptor subunit genes have 
been described, revealing an additional dimension to 
GAB&-receptor complexity [3,4]. The subunit comple- 
ments of native GABA,,-receptors are not kncwn but 
it is thought that different combinations of polypeptides 
assemble to form pcntameric structures analogous to 
the other members of the ligand-gated ion channel su- 
perfamily. In order to approach this problem, we have 
recently described the immunoaffinity purification of 
natural GABA,-receptor subpopulations using anti- 
bodies specific for the al, a2 and rx3 subunits and the 
coexistence of the y2 polypeptide with each of these 
respective subunit-enriched preparations [5]. We now 
Ahitruriutiotts: ELISA. cnzymc linked immunoadsorbcnt usssy; 
GABA, r-aminobutyric acid; KLH, kcyholc limpet hacmocyanin; 
SDS-PAGE, sodium dodccyl sulphate polyacrylamidc gel clcclropho- 
rcsis, 
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report the co-purification of the 83 subunit with the 
different receptor subpopulations using a novel anti-j33 
subunit antibody. 
2. MATERIALS AND METHODS 
Pcptidcs 82 381-395. amino acid sequence KAGLPRHSFWR- 
NALE-NH,, and 83 379-393. amino acid scqucncc KQSM- 
PREGHGRHMDR-NHI, wcrc purchased front Multiple Pcptidc Sys- 
tcms, San Diego. CaliTornia. USA. Both pcptidcs wcrc coupled to 
kcyholc limpet hacmocyanin (KLH) by the glutataldchydc method 
and polyclonal antibodtcs raised in rabbits as in [6]. Anti-pcptidc 
antibody production was monitored by an cnzymc linked immunoad- 
sorbcnt assay (ELISA) and antibodies wcrc purified on the rcspcctivc 
pcptidc-CH Scpharosc 48 affinity column [6,7]. All other materials 
and methods. including the immunoaBinity purhication of GABA,,- 
receptors. wcrc as previously dcscribcd [S-8]. 
3. RESULTS AND DISCUSSION 
WC have previously shown that antibodies raised 
against the N- or C-terminal amino acid sequences of 
the GABA,,-receptor al, a2 and a3 subunits are useful 
probes in that these regions of the polypeptides are 
unique to each of the aforementioned subunits and that 
these antibodies recognise the native conformation of 
receptors in solution [6,7,9]. In selecting candidate 
amino acid sequences for the production of/3 subunit 
isoform-specific antibodies the N- and C-terminal 
regions are not useful, since the C-terminus does not 
extend beyond the fourth transmcmbrane domain and 
is therefore probably inaccessible for antibody binding; 
the respective N-terminal sequcnccs have a high degree 
of identity. Indeed, even the putative intracellular loop, 
a divergent region between a subunit isoforms, has-40% 
amino acid sequence identity thus tcstricting the selec- 
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Fig. I. Immunoblots using an&,93 379-393 CiABA,,-receptor subunit antibodies. Samples were subjected to SDS-PAGE in 10% polyacrylamidc 
slab mini-gels followed by immunobloiling using allinity-purified anlihodics as described [S]. (a) immunoblottingwith anti-@3 379-393 antibodies 
(15 ,ug/ml) with benzodiazepine alIinily chromatography-purified rcccptor as antigen (I pmol [LHJflunilrazepam binding sites. lanes I .3.4 and 6) 
or prcstained prolcin standards with molecular weights as shown on the right (lanes 2,5); (lanes 1.2) antibody alone; (lanes 2,3) amibody 
pre-incubated overnight at 4°C with/I2 381-395. I I.G@l final conccatra:ion; (lancs4.5) antibody pre-incuba~cd overnight at 4’C whh,8l 329-341. 
I I .5,uM final concenlration : (lanes 5.6) antibody prcincubatcd overnight at 4OC with/33 379-393, I I .6pM final conccnlration. (b) immunoblo~~inp 
with Na- deoxycholalc-solubiliscd rcccplor as anligcn (0. I pmol [!H]llunirrazcpam binding sites. lanes I .3 and 4) and bcnzodiazcpinc alI?nily 
chromatography purified receptor (I pmol [‘Hjflunilrazepan binding sites. lanes 2 and 5); (lanes 1.2) blotting wiU1 an&al 326341 antibody. 5 
@ml: (lanes 2.3.4 and 5) blolting with anti-B3 379-393, I5 ,ugh~l where, in lanes 4 and 5, antibody was pre-incubated whh 83 379-393, 1 I .G PM 
final conccnlrntion; (lanes 2.5) prestained standards with molecular weights as shown. Note that in (a), lanes 3 and 5 and in (b), lane 2, werecut 
in hair. 
tion of peptides to sequences /32 381-395 and ,83 379- 
393, Immunisation with both peptide-KLH conjugates 
induced the production of anti-peptide antibodies with 
maximum antibody titres, 1:12 500 @2 381-395) and 
1:40 000 (/33 379-393) but reactivity with GABA,- re- 
ceptors was found with anii-p3 379-393 antibodies 
only, thus this antibody was used for further characteri- 
sation. 
Fig. 1 shows the results obtained for immunoblorting 
with anti-p3 379-393 antibodies using Kn’ deoxycho- 
late detergent-solubilised bovine cerebral cortex or ben- 
zodiazepine affinity chromatography-purified GABA,,- 
receptor as antigen. It can be seen that in both cases 
anti-/33 379-393 antibodies recognise specifically two 
polypeptides with approximately equal intensity with 
M, 59 900 2 500 (n=7) and Mr 57 2UO f 500 (n=7j. The 
molecular weight for the non-glycosylatcd fi3 mature 
subunit predicted from the cDNA sequence is 52 kDa. 
Thep3 subunit contains three consensus equences for 
IV-glycosylation thus once account is taken for the con- 
tribution by weight of the carbohydrate, there is good 
agreement between the predicted and the experimental 
value. The same two immunoreactive species were pres- 
ent in anti-21 324-341, anti-Cys ar2 414-424 and anti- 
Cys u3 454-467 immunoaffinity-purified GABA,,-re- 
ceptors (Fig. 2). Buchstaller et al. [IO] reported recently 
that anti-,03 190-197 antibodies recognised a single po- 
lypeptide with MI, 56 000 in GABA,-rcccptors purified 
from 5-lo-day-old rar brain. Following exhaustive de- 
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Fig. 2. Wcacrn blotting oTimmuno;lffiliily-purified GABA,, rcccplor 
subpopulations. Samples were subjecled IO SDS-PAGE in 10% polya- 
crylamidc mini-slab gels followed by immunoblolting with respeclivc 
artinity-purified a;.:ibodies as described [8]. Amigen used was benzo- 
diazepinc affinity chromatography-purified receptor (I pmol [‘II] flu- 
nhrazcpam binding silts; lanes 2.5 and 8); anti-al 324-341 immunoaf- 
fir&y-purified rcccplor (50 ~1; lmcs I and 3); ami-Cys a2 414-424 
immunoalIinity-purified rcccptor (35 ,ul; lanes 4 and 6); anti-Cys 03 
454467 immunoafXnity_purificd rcccptor (200 ~1; lanes 7 and 9). 
Affinity-purified amibodics used wcrc: anli-al 3X-341, S~gIml, lanes 
I and 2; anti-Cys a2 414-424, 7 &ml, lanes 4 and 5; anli-Cys a3 
454_467,15,@ml, lanes 7 and 8; and anti-/33 37%393,20p&ml, lanes 
2,3,5,&g and 9. The molecular vieighls orprcstaincd prolcin standards 
arc shown on UIC right. Norc IhaI Iancs 2,5 and 8 were GUI in ball: 
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Fig. 3. Dose-dcpcndcm immunopreciphation of ~H]llunitrazcpam- 
specific binding silrs from Na’ dcoxycholaic extracts of bovine ccrc- 
bra1 cortex by anti-/?3 379-393 antibodies. A Na- dcoxycholaw extract 
was prepared from aduh bovine cerebral cortex and the soluble extract 
(200 ~1) was incubated Gth increasing concenlrations of alimity- 
purihcd anti+73 379-393 antibodies diluted with normal rabbit Ig IO 
sivc a fixed protein conccmration per tube. Immune con~plcxcs were 
precipitated by the addition of lmmunoprcciphin and [“H]Runitraze- 
pam binding to the resultant supcrnatams and pellets was carried out 
as described [7]. The rcsulrs arc expressed as the percentage dccreasc 
(supcrnatants, O) or percentage increase (pcllcts, C) of specific [‘HIflu- 
nitrazepam binding sites present following immunoprecipitalion whh 
anti-/I3 379-393 antibodies v&h respect lo control samples which 
contained an equivalcnl concemration of protein A-purified nonim- 
munc rabbit lg. The results arc the mean 2 standard deviations of al 
least four indepcndcnt cxpcrimenrs. 
glycosylation, anti-/I3 190-197 antibodies recognised 
two immunoreactive species with M,. 53 000 and M, 
51 000, which was interpreted as evidence for the exis- 
tence of alternative spliced products of the /33 subunit 
gene. The results obtained here would be in agreement 
with this, with the two immunoreactive species being 
resolved in our SDS-PAGE system before deglycosyla- 
tion. Alternative explanations for our results would be 
that the lower molecular weight species is a proteolytic 
product., p3’, or that the sequence recognised by the 
antibody is common to an as yet unidentified bovine j? 
subunit. Although we cannot distinguish between these 
two possibilities, we would argue against proteolysis 
since the intensity of the two bands is approximately 
equal in all preparations tested and, furthermore, there 
is no evidence in these for the al’ product, a well-char- 
acterised C-terminal-delted proteolytic fragment (Figs. 
1 and 2; [I 11). 
Anti-P3 379-393 antibodies rccognised GABA,-re- 
ccptors in their native detergent-solubilised state as 
demonstrated by their dose-dependent immunoprecipi- 
tation of specific, [3H]flunitrazepam binding sites from 
extracts of bovine cerebral cortex (Fig. 3). The percen- 
tage increase in the binding sites immunoprecipitated 
was always accompanied by a concomitant decrease in 
the [3H]flunitrazepam binding sites in the resultant su- 
pernatants (Fig. 3). It was found that the maximum 
percentage of binding sites immunoprecipitated was 28 
+ 10% (n=4) which is in the same range, i.e. 17%, repor- 
ted by [IO]. We have previously found, using anti-72 
l-15 Cys antibodies, that although dose-dependent im- 
munoprecipitation experiments reached a plateau value, 
re-immunoprecipitation with a second batch of affinity- 
purified antibody resulted in increased precipitation of 
receptor compared to the use of anti-al 324-341 anti- 
bodies, where a maximum value was obtained for a 
single immunoprecipitation [8]. Successive immunopre- 
cipitations with anti-p3 379-393 antibodies did yield an 
increased immunoprecipitation with 33 -t 10% (n=5) 
and 49 + 4% (,z=5) [3H]flunitrazepam binding sites pel- 
leted after one and two immunoprecipitations, respec- 
tively. Control experiments using Protein A purified 
non-immune Ig and anti-al 324-341 antibodies gave no 
increased immunoprecipitation. 
In conclusion, these studies have shown that the 83 
subunit of the GABA,-receptor is both abundant and 
promiscuous in bovine cerebral cortex, being present in 
al, a2 and a3 GABA,-receptor-containing popula- 
tions. Additionally we have provided supportive evi- 
dence in agreement with [lo] for the existence ofalterna- 
rive splice variants of the 83 subunit gene. 
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